Titan Pharmaceuticals Inc. | Mutual Funds
Mutual Funds that own Titan Pharmaceuticals Inc.
Vanguard Total Stock Market Index Fund
311,809
1.47%
0
0%
07/31/2018
Fidelity Spartan Extended Market Index Fund
68,182
0.32%
0
0%
07/31/2018
Vanguard Extended Market Index Fund
45,659
0.22%
210
0%
07/31/2018
30,698
0.14%
0
0%
02/28/2018
WP Large Cap Income Plus Fund
30,000
0.14%
0
0.05%
11/30/2017
20,000
0.09%
0
0.16%
02/28/2018
Fidelity Nasdaq Composite Index
16,442
0.08%
0
0%
07/31/2018
Vanguard Balanced Index Fund
15,719
0.07%
0
0%
07/31/2018
Fidelity Spartan Total Market Index Fund
11,285
0.05%
0
0%
07/31/2018
iShares Core S&P Total US Stock Market ETF
9,424
0.04%
0
0%
09/06/2018
| Address |
400 Oyster Point Boulevard
South San Francisco California 94080
United States
|
|
Employees
|
- |
| Website |
http://www.titanpharm.com |
| Updated |
07/08/2019 |
| Titan Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing proprietary therapeutics primarily for the treatment of medical disorders. Its products include Probuphine, provides non fluctuating blood levels of buprenorphine; Ropinirole implant, which provides dopaminergic stimulation; and T3 implant, which is used in hypothyroidism treatment. Its products are subdermal implants, which utilizes ProNeura drug delivery platform. |
